TRCT
DMRA

Tower Research Capital (TRC)’s Damora Therapeutics DMRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.7K Buy
3,143
+1,725
+122% +$41.8K ﹤0.01% 2346
2026
Q1 		$36.7K Buy
1,418
+1,242
+706% +$31.9K ﹤0.01% 3007
2025
Q4 		$4.05K Sell
176
-1,251
-88% -$21.7K ﹤0.01% 4267
2025
Q3 		$5.31K Buy
1,427
+485
+51% +$1.64K ﹤0.01% 4247
2025
Q2 		$3.21K Sell
942
-641
-40% -$1.9K ﹤0.01% 4534
2025
Q1 		$4.91K Buy
+1,583
New +$7.46K ﹤0.01% 4184
2024
Q4 		– Sell
-346
Closed -$4.2K – 5798
2024
Q3 		$4.2K Buy
346
+205
+145% +$2.68K ﹤0.01% 4635
2024
Q2 		$1.67K Buy
141
+122
+642% +$1.93K ﹤0.01% 5112
2024
Q1 		$374 Sell
19
-295
-94% -$5.25K ﹤0.01% 5510
2023
Q4 		$5.66K Sell
314
-6
-2% -$92 ﹤0.01% 4819
2023
Q3 		$5.77K Buy
320
+238
+290% +$9.35K ﹤0.01% 4690
2023
Q2 		$5.18K Sell
82
-60
-42% -$3.27K ﹤0.01% 4852
2023
Q1 		$7K Sell
142
-164
-54% -$8.65K ﹤0.01% 4738
2022
Q4 		$9K Buy
306
+185
+153% +$7.67K ﹤0.01% 4199
2022
Q3 		$6K Buy
121
+17
+16% +$862 ﹤0.01% 5015
2022
Q2 		$4K Buy
104
+88
+550% +$4.04K ﹤0.01% 5206
2022
Q1 		$1K Buy
+16
New +$899 ﹤0.01% 5789
2021
Q4 		– Sell
-525
Closed -$47K – 6292
2021
Q3 		$47K Buy
525
+210
+67% +$22.5K ﹤0.01% 3015
2021
Q2 		$40K Buy
+315
New +$42.9K ﹤0.01% 3207

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Tower Research Capital (TRC)'s DMRA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Damora Therapeutics (DMRA) stake by 122% in Q2 2026, buying an estimated $41.8K and bringing the position to 3,143 shares worth $81.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2346.

Tower Research Capital (TRC) first reported a position in DMRA in Q2 2021 and has held it in 19 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Tower Research Capital (TRC) held 3,143 shares of Damora Therapeutics worth $81.7K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,725 Damora Therapeutics shares in Q2 2026, an estimated $41.8K.
  • Damora Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2346 holding.
  • Tower Research Capital (TRC) first reported a position in Damora Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.